Computational Development of New Inhibitors for Apoptosis Stimulating Protein of p53 (iASPP) Using Pharmacophore Modeling, Docking, and MD Simulation Approaches
DOI:
https://doi.org/10.62382/jcbt.v1i2.27Keywords:
Pharmacophore Model, Validation, Molecular Docking, Molecular Dynamics SimulationAbstract
Inhibitor of apoptosis-stimulating protein of p53 (iASPP) overexpression is associated with diverse human tumors, including lung cancer, colorectal cancer, prostate cancer, acute leukemia, hepatocellular carcinoma, cervical cancer, and ovarian cancer. This study aims to find new and potent inhibitors for the iASPP drug target. Using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation an integrated strategy was developed to find highly effective iASPP inhibitors. Subsequently, the pharmacophore model was employed as a screening query to find promising inhibitors from the ZINC database. Total 36/12000 hits were identified against the iASPP drug target. The binding mode of the promising identified inhibitors was predicted by a molecular docking study. To evaluate the stability of the newly identified inhibitors top 03 best docking scores compounds were subjected to MD simulation. MD simulation and binding energy calculation confirmed that the compounds including ZINC001361049159, ZINC001361124195, and ZINC001545869876 were stable. The MD simulation analysis indicated that among all the compounds ZINC001361049159 was the most potent. These newly designed iASPP inhibitors could be used as starting material to identify new and potent anti-cancer drugs.
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. A Cancer Journal for Clinicians. 2018, 68, 7-30. DOI: 10.3322/caac.21442
Jia Y, Yun CH, Park E, Ercan D, Manuia M, et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016, 534, 129-32. DOI: 10.1038/nature17960
Shi D, Gu W. Dual roles of MDM2 in the regulation of p53: ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes & Cancer. 2012, 3, 240-8. DOI: 10.1177/1947601912455199
Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology.2010, 2, a001008. DOI: 10.1101/cshperspect.a001008
Muller PA, Vousden KH. p53 mutations in cancer. Nature Cell Biology. 2013, 15, 2-8. DOI: 10.1038/ncb2641
Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nature Reviews Cancer. 2014, 14, 359-70. DOI: 10.1038/nrc3711
Liu Z, Zhang X, Huang D, Liu Y, Zhang X, et al. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance. Medical Oncology. 2012, 29, 3381-8. DOI: 10.1007/s12032-012-0306-9
Cai Y, Qiu S, Gao X, Gu SZ, Liu ZJ. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Apoptosis. 2012, 17, 777-83. DOI: 10.1007/s10495-012-0728-z
Dong P, Ihira K, Hamada J, Watari H, Yamada T, et al. Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget. 2015, 6, 19968. DOI: 10.18632/oncotarget.4847
Qiu S, Cai Y, Gao X, Gu SZ, Liu ZJ. A small peptide derived from p53 linker region can resume the apoptotic activity of p53 by sequestering iASPP with p53. Cancer Letters. 2015, 356, 910-7. DOI: 10.1016/j.canlet.2014.10.044
Sertkaya A, Beleche T, Jessup A, Sommers BD. Costs of drug development and research and development intensity in the US, 2000-2018. JAMA Network Open. 2024, 7, e2415445-e. DOI: 10.1001/jamanetworkopen.2024.15445
Ece A. Computer-aided drug design. BMC Chemistry. 2023, 17, 26. DOI: 10.1186/s13065-023-00939-w
Zhou Y, Tang S, Chen T, Niu MM. Structure-based pharmacophore modeling, virtual screening, molecular docking and biological evaluation for identification of potential poly (ADP-Ribose) polymerase-1 (PARP-1) inhibitors. Molecules. 2019, 24, 4258. DOI: 10.3390/molecules24234258
Ramírez D, Concha G, Arévalo B, Prent-Peñaloza L, Zúñiga L, et al. Discovery of novel TASK-3 channel blockers using a pharmacophore-based virtual screening. International Journal of Molecular Sciences. 2019, 20, 4014. DOI: 10.3390/ijms20164014
Chen S, Wu J, Zhong S, Li Y, Zhang P, et al. iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. Proceedings of the National Academy of Sciences. 2019, 116, 17470-9, (2019). DOI: 10.1073/pnas.1909393116
Ghufran M, Rehman AU, Ayaz M, Ul-Haq Z, Uddin R, et al. New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and in vitro assays. Journal of Biomolecular Structure and Dynamics. 2023, 41, 8053-67. DOI: 10.1080/07391102.2022.2128878
Castleman P, Szwabowski G, Bowman D, Cole J, Parrill A, et al. Ligand-based G Protein Coupled Receptor pharmacophore modeling: Assessing the role of ligand function in model development. Journal of Molecular Graphics and Modelling. 2022, 111, 108107. DOI: 10.1016/j.jmgm.2021.108107
Ghosh A, Mukherjee S, Jha PC, Manhas A. Identifying natural product inhibitors against CDK9 enzyme via combined multicomplex-based pharmacophore modeling, interaction studies and molecular dynamics simulations. Computers in Biology and Medicine. 2023, 161, 107055. DOI: 10.1016/j.compbiomed.2023.107055
Ullah H, Nawaz A, Rahim F, Uddin I, Hussain A, et al. Synthesis, in vitro β-glucuronidase inhibitory potential and molecular docking study of benzimidazole analogues. Chemical Data Collections. 2023, 44, 100996. DOI:10.1016/j.cdc.2023.100996
Kumari R, Dalal V. Identification of potential inhibitors for LLM of Staphylococcus aureus: structure-based pharmacophore modeling, molecular dynamics, and binding free energy studies. Journal of Biomolecular Structure and Dynamics. 2022, 40, 9833-47. DOI: 10.1080/07391102.2021.1936179
Dhankhar P, Dalal V, Singh V, Tomar S, Kumar P. Computational guided identification of novel potent inhibitors of N-terminal domain of nucleocapsid protein of severe acute respiratory syndrome coronavirus 2. Journal of Biomolecular Structure and Dynamics. 2022, 40, 4084-99. DOI: 10.1080/07391102.2020.1852968
Kumari R, Rathi R, Pathak SR, Dalal V. Structural-based virtual screening and identification of novel potent antimicrobial compounds against YsxC of Staphylococcus aureus. Journal of Molecular Structure. 2022, 1255, 132476. DOI: 10.1016/j.molstruc.2022.132476
Ahmad S, Khan M, Alam A, Ajmal A, Wadood A, et al. Novel flurbiprofen clubbed oxadiazole derivatives as potential urease inhibitors and their molecular docking study. RSC Advances. 2023, 13, 25717-28. DOI: 10.1039/d3ra03841f
Ali H, Samad A, Ajmal A, Ali A, Ali I, et al. Identification of drug targets and their inhibitors in Yersinia pestis strain 91001 through subtractive genomics, machine learning, and MD simulation approaches. Pharmaceuticals. 2023, 16, 1124. DOI: 10.3390/ph16081124
Ajmal A, Mahmood A, Hayat C, Hakami MA, Alotaibi BS, et al. Computer-assisted drug repurposing for thymidylate kinase drug target in monkeypox virus. Frontiers in Cellular and Infection Microbiology. 2023, 13, 1159389, (2023). DOI: 10.3389/fcimb.2023.1159389
Hussein D, Saka M, Baeesa S, Bangash M, Alghamdi F, et al. Structure-based virtual screening and molecular docking approaches to identify potential inhibitors against KIF2C to combat glioma. Journal of Biomolecular Structure and Dynamics. (online ahead of print 20231109;doi:10.1080/07391102.2023.2278750), 2023, 1-14. DOI: 10.1080/07391102.2023.2278750
Wadood A, Ajmal A, Junaid M, Rehman AU, Uddin R, et al. Machine learning-based virtual screening for STAT3 anticancer drug target. Current Pharmaceutical Design. 2022, 28, 3023-32. DOI: 10.2174/1381612828666220728120523
Ajmal A, Ali Y, Khan A, Wadood A, Rehman AU. Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling. Journal of Biomolecular Structure and Dynamics. 2023, 41, 8866-75. DOI: 10.1080/07391102.2022.2138550
Junaid M, Khan MT, Malik SI, Wei DQ. Insights into the mechanisms of the pyrazinamide resistance of three pyrazinamidase mutants N11K, P69T, and D126N. Journal of Chemical Information and Modeling. 2018, 59, 498-508. DOI: 10.1021/acs.jcim.8b00525
Ullah S, Junaid M, Liu Y, Chen S, Zhao Y, et al. Validation of catalytic site residues of Ubiquitin Specific Protease 2 (USP2) by molecular dynamic simulation and novel kinetics assay for rational drug design. Molecular Diversity. 2023, 27, 1323-32. DOI: 10.1007/s11030-022-10499-1
Zhang S, Zhou L, El-Deiry WS. Small-molecule NSC59984 induces mutant p53 degradation through a ROS-ERK2-MDM2 Axis in cancer cells. Molecular Cancer Research. 2022, 20, 622-36. DOI: 10.1158/1541-7786.MCR-21-0149
Khan A, Junaid M, Li CD, Saleem S, Humayun F, et al. Dynamics insights into the gain of flexibility by Helix-12 in ESR1 as a mechanism of resistance to drugs in breast cancer cell lines. Frontiers in Molecular Biosciences. 2020, 6, 159. DOI: 10.3389/fmolb.2019.00159
Junaid M, Shah M, Khan A, Li CD, Khan MT, et al. Structural-dynamic insights into the H. pylori cytotoxin-associated gene A (CagA) and its abrogation to interact with the tumor suppressor protein ASPP2 using decoy peptides. Journal of Biomolecular Structure and Dynamics. 2019, 37, 4035-50. DOI: 10.1080/07391102.2018.1537895
Laplagne C, Domagala M, Le Naour A, Quemerais C, Hamel D, et al. Latest advances in targeting the tumor microenvironment for tumor suppression. International Journal of Molecular Sciences. 2019, 20, 4719. DOI: 10.3390/ijms20194719
Bedoui S, Herold MJ, Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nature Reviews Molecular Cell Biology. 2020, 21, 678-95. DOI: 10.1038/s41580-020-0270-8
Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2023, 10, 1367-401. DOI: 10.1016/j.gendis.2022.02.007
Ioele G, Chieffallo M, Occhiuzzi MA, De Luca M, Garofalo A, et al. Anticancer drugs: recent strategies to improve stability profile, pharmacokinetic and pharmacodynamic properties. Molecules. 2022, 27, 5436. DOI: 10.3390/molecules27175436
Lu S, Li Y, Zhu C, Wang W, Zhou Y. Managing cancer drug resistance from the perspective of inflammation. Journal of Oncology. 2022, 2022, 3426407. DOI: 10.1155/2022/3426407
Tanrikulu Y, Krüger B, Proschak E. The holistic integration of virtual screening in drug discovery. Drug Discovery Today. 2013, 18, 358-64. DOI: 10.1016/j.drudis.2013.01.007
Schuster D, Spetea M, Music M, Rief S, Fink M, et al. Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors. Bioorganic & Medicinal Chemistry. 2010, 18, 5071-80. DOI: 10.1016/j.bmc.2010.05.071
Vuorinen A, Schuster D. Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. Methods. 2015, 71, 113-34. DOI: 10.1016/j.ymeth.2014.10.013
Rafiq H, Hu J, Hakami MA, Hazazi A, Alamri MA, et al. Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations. Scientific Reports. 2023, 13, 20147, (2023). DOI: 10.1038/s41598-023-46193-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Cancer Biomoleculars and Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
